Invokana Lawsuit Filings Mount, As Litigation Involving Ketoacidosis and Kidney Damage Allegations Grows, Bernstein Liebhard LLP Reports
Court records indicate that one of the most recent claims was filed in the District of New Jersey on April 13th by a plaintiff who allegedly suffered severe kidney damage and diabetic ketoacidosis after being prescribed Invokana in October 2015. This and other Invokana lawsuits assert that Johnson & Johnson and its Janssen Pharmaceuticals unit knew about the increased risk of severe injury among Invokana users, yet failed to warn consumers or the medical community. (Case No. 3:16-cv-02050-MAS-DEA)
"Our Firm has heard from numerous Invokana patients since federal health regulators began investigating it and other SGLT2 inhibitor medications in May 2015, and those inquiries have only accelerated since the drugs' labels were updated with new ketoacidosis warnings in December. We are not surprised that the litigation involving Invokana is growing at such a rapid rate," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is investigating potential Invokana lawsuits on behalf of Type 2 diabetes patients who were diagnosed with ketoacidosis or kidney damage, allegedly due to their use of this or another SGLT2 inhibitor.
Invokana Side Effects
Approved by the U.S. Food & Drug Administration (FDA) in March 2013, Invokana was the first SGLT2 inhibitor approved by the FDA to treat Type 2 diabetes. Other medications in this class include Invokamet, Jardiance, Farxiga, Xigduo XR and Glyxambi.
In May 2015, the FDA disclosed that it was investigating the entire SGLT2 inhibitor class after the drugs were implicated in numerous reports of diabetic ketoacidosis, a disorder in which toxic acids called ketones accumulate in the blood stream. On December 4, 2015, the FDA announced that the "Warnings and Precautions" section on all SGLT2 inhibitors labels would include new information regarding a potential risk of ketoacidosis. The labels were also modified with information about life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that originate as urinary tract infections.
Diabetic ketoacidosis is a dangerous condition that can result in diabetic coma and death. The FDA recommends that patients stop taking their SGLT2 inhibitor and seek medical attention immediately if they develop any symptoms of ketoacidosis, including: nausea, vomiting, abdominal pain, tiredness, and trouble breathing.
Bernstein Liebhard LLP is currently evaluating potential Invokana lawsuits on behalf of Type 2 diabetics who were diagnosed with ketoacidosis or kidney damage while using this drug or any other SGLT2 inhibitor. To learn more, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP